A. Agarwal, P. Mehrotra, M. Jain, S. Gupta, A. Mishra et al., Size of the Tumor and Pheochromocytoma of the Adrenal Gland Scaled Score (PASS): Can They Predict Malignancy?, World Journal of Surgery, vol.29, issue.9, pp.3022-3028, 2010.
DOI : 10.1007/BF03345810

Y. Anouar, S. Jegou, D. Alexandre, I. Lihrmann, J. Conlon et al., Molecular cloning of frog secretogranin II reveals the occurrence of several highly conserved potential regulatory peptides, FEBS Letters, vol.66, issue.3, pp.295-299, 1996.
DOI : 10.1046/j.1471-4159.1996.66062248.x

Y. Anouar, Y. L. Desmoucelles, C. Leprince, J. Breault, L. Gallo-payet et al., Identification of a novel secretogranin II-derived peptide in the adult and fetal human adrenal gland, Endocrine Research, vol.93, issue.3-4, pp.731-736, 1998.
DOI : 10.1073/pnas.93.9.4431

S. Benjannet, N. Rondeau, L. Paquet, A. Boudreault, C. Lazure et al., Comparative biosynthesis, covalent post-translational modifications and efficiency of prosegment cleavage of the prohormone convertases PC1 and PC2: glycosylation, sulphation and identification of the intracellular site of prosegment cleavage of PC1 and PC2, Biochemical Journal, vol.294, issue.3, pp.735-743, 1993.
DOI : 10.1042/bj2940735

M. Boutahricht, J. Guillemot, M. Montero-hadjadje, S. Bellafqih, E. Ouezzani et al., Biochemical Characterisation and Immunohistochemical Localisation of the Secretogranin II-Derived Peptide EM66 in the Hypothalamus of the Jerboa (Jaculus orientalis): Modulation by Food Deprivation, Journal of Neuroendocrinology, vol.132, issue.6, pp.372-378, 2005.
DOI : 10.1007/978-3-642-68289-6

M. Boutahricht, J. Guillemot, M. Montero-hadjadje, Y. Barakat, E. Ouezzani et al., Immunohistochemical distribution of the secretogranin II-derived peptide EM66 in the rat hypothalamus: A comparative study with jerboa, Neuroscience Letters, vol.414, issue.3, pp.268-272
DOI : 10.1016/j.neulet.2006.12.033
URL : https://hal.archives-ouvertes.fr/hal-01706443

P. Chomczynski and N. Sacchi, Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction, Analytical Biochemistry, vol.162, issue.1, pp.156-159, 1987.
DOI : 10.1016/0003-2697(87)90021-2

A. Chrisoulidou, G. Kaltsas, I. Ilias, and A. Grossman, The diagnosis and management of malignant phaeochromocytoma and paraganglioma, Endocrine Related Cancer, vol.14, issue.3, pp.569-585, 2007.
DOI : 10.1677/ERC-07-0074
URL : http://erc.endocrinology-journals.org/content/14/3/569.full.pdf

B. Colombo, F. Curnis, C. Foglieni, A. Monno, G. Arrigoni et al., Chromogranin A expression in neoplastic cells affects tumor growth and morphogenesis in mouse models, Cancer Research, vol.62, pp.941-946, 2002.

J. Conlon, Granin-derived peptides as diagnostic and prognostic markers for endocrine tumors, Regulatory Peptides, vol.165, issue.1, pp.5-11, 2010.
DOI : 10.1016/j.regpep.2009.11.013

A. Dittie and S. Tooze, Characterization of the endopeptidase PC2 activity towards secretogranin II in stably transfected PC12 cells, Biochemical Journal, vol.310, issue.3, pp.777-787, 1995.
DOI : 10.1042/bj3100777

U. Eder, R. Fischer-colbrie, P. Kogner, B. Leitner, P. Bjellerup et al., Levels and molecular forms of chromogranins in human childhood neuroblastomas and ganglioneuromas, Neuroscience Letters, vol.253, issue.1, pp.17-20, 1998.
DOI : 10.1016/S0304-3940(98)00588-6

G. Eisenhofer, J. Lenders, G. Siegert, S. Bornstein, P. Friberg et al., Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status, European Journal of Cancer, vol.48, issue.11, 2011.
DOI : 10.1016/j.ejca.2011.07.016

R. Fischer-colbrie, A. Laslop, and . Kirchmair, Secretogranin II: Molecular properties, regulation of biosynthesis and processing to the neuropeptide secretoneurin, Progress in Neurobiology, vol.46, issue.1, pp.49-70, 1995.
DOI : 10.1016/0301-0082(94)00060-U

R. Fischer-colbrie, R. Kirchmair, C. Kahler, C. Wiedermann, and A. Saria, Secretoneurin: A New Player in Angiogenesis and Chemotaxis Linking Nerves, Blood Vessels and the Immune System, Current Protein & Peptide Science, vol.6, issue.4, pp.373-385, 2005.
DOI : 10.2174/1389203054546334

B. Gao, F. Meng, W. Bian, J. Chen, H. Zhao et al., Development and validation of pheochromocytoma of the adrenal gland scaled score for predicting malignant pheochromocytomas, Urology, vol.68, issue.2, pp.282-286, 2006.
DOI : 10.1016/j.urology.2006.02.019

M. Guerin, J. Guillemot, E. Thouennon, A. Pierre, F. El-yamani et al., Granins and their derived peptides in normal and tumoral chromaffin tissue: Implications for the diagnosis and prognosis of pheochromocytoma, Regulatory Peptides, vol.165, issue.1, pp.21-29, 2010.
DOI : 10.1016/j.regpep.2010.06.003

J. Guillemot, Y. Anouar, M. Montero-hadjadje, E. Grouzmann, L. Grumolato et al., Circulating EM66 is a highly sensitive marker for the diagnosis and follow-up of pheochromocytoma, International Journal of Cancer, vol.24, issue.8, pp.2003-2012, 2006.
DOI : 10.1001/jama.288.3.314

J. Hoflehner, U. Eder, A. Laslop, N. Seidah, R. Fischer-colbrie et al., Processing of secretogranin II by prohormone convertases: importance of PC1 in generation of secretoneurin, FEBS Letters, vol.360, issue.95, pp.294-298, 1995.

R. Ischia, R. Gasser, R. Fischer-colbrie, U. Eder, A. Pagani et al., Levels and Molecular Properties of Secretoneurin-Immunoreactivity in the Serum and Urine of Control and Neuroendocrine Tumor Patients, Journal of Clinical Endocrinology & Metabolism, vol.85, issue.1, pp.355-360, 2000.
DOI : 10.1210/jc.85.1.355

R. Ischia, A. Hobisch, R. Bauer, U. Weiss, R. Gasser et al., ELEVATED LEVELS OF SERUM SECRETONEURIN IN PATIENTS WITH THERAPY RESISTANT CARCINOMA OF THE PROSTATE, The Journal of Urology, vol.163, issue.4, pp.1161-1164, 2000.
DOI : 10.1016/S0022-5347(05)67714-2

V. Kantorovich and K. Pacak, Pheochromocytoma and Paraganglioma, Pheochromocytoma and paraganglioma . Progress in Brain Research, vol.182, issue.10, pp.343-373, 2010.
DOI : 10.1016/S0079-6123(10)82015-1

D. Karasek, Z. Frysak, and K. Pacak, Genetic Testing for Pheochromocytoma, Current Hypertension Reports, vol.3, issue.Suppl 5, pp.456-464, 2010.
DOI : 10.1093/qjmed/77.2.1151

T. Konoshita, J. Gasc, E. Villard, R. Takeda, and N. Seidah, Expression of PC2 and PC1/PC3 in human pheochromocytomas, Molecular and Cellular Endocrinology, vol.99, issue.2, pp.307-314
DOI : 10.1016/0303-7207(94)90022-1

A. Laslop, C. Weiss, D. Savaria, C. Eiter, S. Tooze et al., Proteolytic Processing of Chromogranin B and Secretogranin II by Prohormone Convertases, Journal of Neurochemistry, vol.70, issue.1, pp.374-383, 1998.
DOI : 10.1046/j.1471-4159.1998.70010374.x

G. Meyer-rochow, N. Jackson, J. Conaglen, D. Whittle, M. Kunnimalaiyaan et al., MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets, Endocrine Related Cancer, vol.17, issue.3, pp.835-846, 2010.
DOI : 10.1677/ERC-10-0142

M. Montero-hadjadje, S. Vaingankar, S. Elias, H. Tostivint, S. Mahata et al., Chromogranins A and B and secretogranin II: evolutionary and functional aspects, Acta Physiologica, vol.146, issue.2, pp.309-324, 2008.
DOI : 10.1111/j.1476-5381.1967.tb01980.x

L. Muller and C. Tougard, Production and secretion of N-terminal secretogranin II derived peptides in GH3B6 prolactin cells, Molecular and Cellular Endocrinology, vol.112, issue.1, pp.101-112, 1995.
DOI : 10.1016/0303-7207(95)03594-W
URL : https://hal.archives-ouvertes.fr/hal-02125550

A. Pagani, M. Forni, G. Tonini, M. Papotti, and G. Bussolati, Expression of Members of the Chromogranin Family in Primary Neuroblastomas, Diagnostic Molecular Pathology, vol.1, issue.1, pp.16-24, 1992.
DOI : 10.1097/00019606-199203000-00003

C. Papewalis, C. Kouatchoua, M. Ehlers, B. Jacobs, D. Porwol et al., Chromogranin A as potential target for immunotherapy of malignant pheochromocytoma, Molecular and Cellular Endocrinology, vol.335, issue.1, pp.69-77, 2011.
DOI : 10.1016/j.mce.2010.05.021

J. Peinado, R. Vazquez-martinez, D. Cruz-garcia, A. Ruiz-navarro, Y. Anouar et al., Differential Expression and Processing of Chromogranin A and Secretogranin II in Relation to the Secretory Status of Endocrine Cells, Endocrinology, vol.147, issue.3, pp.1408-1418, 2006.
DOI : 10.1210/en.2005-0975

G. Portela-gomes, M. Stridsberg, L. Grimelius, U. Falkmer, and . Falkmer, Expression of chromogranins A, B, and C (secretogranin II) in human adrenal medulla and in benign and malignant pheochromocytomas An immunohistochemical study with region-specific antibodies, APMIS, vol.141, issue.10, pp.663-673, 2004.
DOI : 10.1097/00000478-200205000-00002

G. Portela-gomes, L. Grimelius, E. Wilander, and M. Stridsberg, Granins and granin-related peptides in neuroendocrine tumours, Regulatory Peptides, vol.165, issue.1, pp.12-20, 2010.
DOI : 10.1016/j.regpep.2010.02.011

P. Rosa and H. Gerdes, The granin protein family: Markers for neuroendocrine cells and tools for the diagnosis of neuroendocrine tumors, Journal of Endocrinological Investigation, vol.85, issue.3, pp.207-225, 1994.
DOI : 10.1172/JCI114604

D. Rosenberg, L. Groussin, E. Jullian, K. Perlemoine, S. Medjane et al., Transcription Factor 3???,5???-Cyclic Adenosine 5???-Monophosphate-Responsive Element-Binding Protein (CREB) Is Decreased during Human Adrenal Cortex Tumorigenesis and Fetal Development, The Journal of Clinical Endocrinology & Metabolism, vol.88, issue.8, pp.3958-3965, 2003.
DOI : 10.1210/jc.2003-030070

J. Scammell, S. Reddy, D. Valentine, T. Coker, S. Nikolopoulos et al., Isolation and characterization of the human secretogranin II gene promoter, Molecular Brain Research, vol.75, issue.1, pp.8-15, 2000.
DOI : 10.1016/S0169-328X(99)00269-7

M. Schober, R. Fischer-colbrie, K. Schmid, G. Bussolati, O. Connor et al., Comparison of chromogranins A, B, and secretogranin II in human adrenal medulla and pheochromocytoma, Laboratory Investigation, vol.57, pp.385-391, 1987.

L. Scopsi, M. Gullo, F. Rilke, S. Martin, and D. Steiner, Proprotein convertases (PC1/PC3 and PC2) in normal and neoplastic human tissues: their use as markers of neuroendocrine differentiation, Journal of Clinical Endocrinology and Metabolism, vol.80, pp.294-301, 1995.

W. Shyu, S. Lin, M. Chiang, D. Chen, C. Su et al., Secretoneurin promotes neuroprotection and neuronal plasticity via the Jak2/Stat3 pathway in murine models of stroke, Journal of Clinical Investigation, vol.118, issue.1, pp.133-148, 2008.
DOI : 10.1172/JCI32723

S. Song, M. Rhee, M. Roberson, R. Maurer, and K. Kim, , 2003.

, Gonadotropin-releasing hormone-induced stimulation of the rat secretogranin II promoter involves activation of CREB, Molecular and Cellular Endocrinology, vol.199, issue.02, pp.29-36

M. Stridsberg, B. Eriksson, and E. Janson, Measurements of secretogranins II, III, V and proconvertases 1/3 and 2 in plasma from patients with neuroendocrine tumours, Regulatory Peptides, vol.148, issue.1-3, pp.95-98, 2008.
DOI : 10.1016/j.regpep.2008.03.007

I. Suh, D. Shibru, G. Eisenhofer, K. Pacak, Q. Duh et al., Candidate Genes Associated With Malignant Pheochromocytomas by Genome-Wide Expression Profiling, Annals of Surgery, vol.250, issue.6, pp.983-990, 2009.
DOI : 10.1097/SLA.0b013e3181b248bb

K. Tano, A. Oyabu, Y. Tashiro, N. Kamada, N. Narita et al., Manserin, a secretogranin II-derived peptide, distributes in the rat endocrine pancreas colocalized with islet-cell specific manner, Histochemistry and Cell Biology, vol.164, issue.1, pp.53-57, 2010.
DOI : 10.1177/002215540305100812

L. Thompson, Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) to Separate Benign From Malignant Neoplasms, The American Journal of Surgical Pathology, vol.26, issue.5, pp.551-566, 2002.
DOI : 10.1097/00000478-200205000-00002

E. Thouënnon, A. Elkahloun, J. Guillemot, A. Gimenez-roqueplo, J. Bertherat et al., Identification of Potential Gene Markers and Insights into the Pathophysiology of Pheochromocytoma Malignancy, The Journal of Clinical Endocrinology & Metabolism, vol.92, issue.12, pp.4865-4872, 2007.
DOI : 10.1210/jc.2007-1253

E. Thouënnon, A. Pierre, J. Guillemot, Y. L. Eisenhofer, and G. Anouar, Genetic markers for the diagnosis and prognosis of pheochromocytoma, Expert Review of Endocrinology & Metabolism, vol.103, issue.1, pp.45-52, 2009.
DOI : 10.1007/BF01938677

E. Thouënnon, A. Pierre, Y. Tanguy, J. Guillemot, D. Manecka et al., Expression of trophic amidated peptides and their receptors in benign and malignant pheochromocytomas: high expression of adrenomedullin RDC1 receptor and implication in tumoral cell survival, Endocrine Related Cancer, vol.17, issue.3, pp.637-651, 2010.
DOI : 10.1677/ERC-10-0109

H. Timmers, F. Brouwers, A. Hermus, F. Sweep, A. Verhofstad et al., Metastases but not cardiovascular mortality reduces life expectancy following surgical resection of apparently benign pheochromocytoma, Endocrine Related Cancer, vol.15, issue.4, pp.1127-1133, 2008.
DOI : 10.1677/ERC-08-0049

V. Turquier, Y. L. Grumolato, L. Alexandre, D. Fournier, A. Vaudry et al., Pituitary Adenylate Cyclase-Activating Polypeptide Stimulates Secretoneurin Release and Secretogranin II Gene Transcription in Bovine Adrenochromaffin Cells through Multiple Signaling Pathways and Increased Binding of Pre-Existing Activator Protein-1-Like Transcription Factors, Molecular Pharmacology, vol.60, issue.1, pp.42-52, 2001.
DOI : 10.1124/mol.60.1.42

V. Vallet, B. Griffond, M. Clavequin, M. De-monti, D. Fellmann et al., Early detection of secretogranin-II (SgII) in the human fetal pituitary: immunocytochemical study using an antiserum raised against a human recombinant SgII., Endocrinology, vol.136, issue.5, pp.2074-2081, 1995.
DOI : 10.1210/endo.136.5.7720657

V. Vallet, J. Li, and J. Duval, Secretogranin II (SgII) distribution and processing studies in human normal and adenomatous anterior pituitaries using new polyclonal antibodies, Regulatory Peptides, vol.68, issue.3, pp.155-163, 1997.
DOI : 10.1016/S0167-0115(96)02110-6

A. Van-horssen and G. Martens, Biosynthesis of secretogranin II in Xenopus intermediate pituitary, Molecular and Cellular Endocrinology, vol.147, issue.1-2, pp.57-64, 1999.
DOI : 10.1016/S0303-7207(98)00219-6

J. Waldmann, V. Fendrich, J. Holler, M. Buchholz, E. Heinmoller et al., , 2010.

, Microarray analysis reveals differential expression of benign and malignant pheochromocytoma, Endocrine-Related Cancer, vol.17, pp.743-756

H. Winkler and R. Fischer-colbrie, The chromogranins A and B: The first 25 years and future perspectives, Neuroscience, vol.49, issue.3, pp.497-528, 1992.
DOI : 10.1016/0306-4522(92)90222-N

D. Wu, A. Tischler, R. Lloyd, R. Delellis, R. De-krijger et al., Observer Variation in the Application of the Pheochromocytoma of the Adrenal Gland Scaled Score, The American Journal of Surgical Pathology, vol.33, issue.4, pp.599-608, 2009.
DOI : 10.1097/PAS.0b013e318190d12e

A. Yajima, M. Ikeda, K. Miyazaki, T. Maeshima, N. Narita et al., Manserin, a novel peptide from secretogranin II in the neuroendocrine system, NeuroReport, vol.15, issue.11, pp.1755-1759, 2004.
DOI : 10.1097/01.wnr.0000127634.38052.84

A. Yajima, N. Narita, and M. Narita, Recently identified a novel neuropeptide manserin colocalize with the TUNEL-positive cells in the top villi of the rat duodenum, Journal of Peptide Science, vol.163, issue.6, pp.773-776, 2008.
DOI : 10.1016/0016-5085(88)90374-5

L. Yon, J. Guillemot, M. Montero-hadjadje, L. Grumolato, J. Leprince et al., Malignant Tumors, The Journal of Clinical Endocrinology & Metabolism, vol.88, issue.6, pp.2579-2585, 1210.
DOI : 10.1210/jc.2002-021748
URL : https://hal.archives-ouvertes.fr/hal-01706414

E. Zhao, A. Basak, K. Crump, and V. Trudeau, Proteolytic processing and differential distribution of secretogranin-II in goldfish, General and Comparative Endocrinology, vol.146, issue.2, pp.100-107, 2006.
DOI : 10.1016/j.ygcen.2005.10.007

E. Zhao, H. Hu, and V. Trudeau, Secretoneurin as a hormone regulator in the pituitary, Regulatory Peptides, vol.165, issue.1, pp.117-122, 2010.
DOI : 10.1016/j.regpep.2009.11.019